PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate Cancer

BACKGROUND: PTEN is the most commonly deleted tumor suppressor gene in primary prostate cancer (PCa) and its loss is associated with poor clinical outcomes and ERG gene rearrangement. OBJECTIVE: We tested whether PTEN loss is associated with shorter recurrence-free survival (RFS) in surgically treat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur Urol Focus
Hlavní autoři: Lotan, Tamara L., Wei, Wei, Morais, Carlos L., Hawley, Sarah T., Fazli, Ladan, Hurtado-Coll, Antonio, Troyer, Dean, McKenney, Jesse K., Simko, Jeffrey, Carroll, Peter R., Gleave, Martin, Lance, Raymond, Lin, Daniel W., Nelson, Peter S., Thompson, Ian M., True, Lawrence D., Feng, Ziding, Brooks, James D.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5014432/
https://ncbi.nlm.nih.gov/pubmed/27617307
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.euf.2015.07.005
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky